This study is for people with multiple myeloma (a type of blood cancer) who also have renal failure (kidney problems). The treatment involves four cycles of a drug combination called Dara-CyBorD, which includes daratumumab-hyaluronidase (dara SC), cyclophosphamide, bortezomib, and dexamethasone. The goal is to see how well this treatment works and how it may affect kidney function.

Patients will receive the treatment for four cycles, each lasting 28 days. After this, doctors will assess the response with scans and tests. Depending on the results, further steps might include more cycles or different treatments based on whether you can have a transplant. If you join the study, you'll be followed up every three months for up to two years.

• Participants receive free treatment and regular health check-ups.
• You might help improve treatments for others with similar conditions.
• Risks include side effects from the drugs and frequent hospital visits.